

Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

Anti-RAGE, clone DD/A11 or mAbA11

RRID:AB_95213

Type: Antibody

Proper Citation

Millipore Cat# MAB5328, RRID:AB_95213

Antibody Information

URL: http://antibodyregistry.org/AB_95213

Proper Citation: Millipore Cat# MAB5328, RRID:AB_95213

Target Antigen: RAGE clone DD/A11 or mAbA11

Host Organism: mouse

Clonality: monoclonal

Comments: seller recommendations: IgG2a; IgG2a ELISA, IC, IH, WB; Western Blot; Immunocytochemistry; Immunohistochemistry; ELISA
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Anti-RAGE, clone DD/A11 or mAbA11

Description: This monoclonal targets RAGE clone DD/A11 or mAbA11

Target Organism: b, h, m

Antibody ID: AB_95213

Vendor: Millipore

Catalog Number: MAB5328

Record Creation Time: 20250820T052521+0000

Record Last Update: 20250820T213157+0000

Ratings and Alerts

- Independent validation by the NYU Langone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Anti-RAGE, clone DD/A11 or mAbA11.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tang JY, et al. (2026) Hepatic expression of APOE3 Christchurch mitigates APOE4-related Alzheimer's disease pathologies in mice. Neuron.

Yu ZY, et al. (2025) Roles of blood monocytes carrying TREM2R47H mutation in pathogenesis of Alzheimer's disease and its therapeutic potential in APP/PS1 mice. Alzheimer's & dementia : the journal of the Alzheimer's Association, 21(2), e14402.

Yu ZY, et al. (2022) Inhibiting β 1-adrenergic receptor signaling pathway ameliorates AD-type pathologies and behavioral deficits in APP^{swe}/PS1 mouse model. Journal of neurochemistry, 161(3), 293.